Head to head
GlaxoSmithKline vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: GSK · LLY
GSK
GlaxoSmithKline
50.33-0.16%
1-year price shape — +11% over the period
Quant Rating D · 50/100
vs
LLY
Eli Lilly and Co
1,354.00-0.79%
1-year price shape — +45% over the period
Quant Rating B · 84/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (84); Eli Lilly and Co has done best over the past year (+45%); Eli Lilly and Co earns the most per share.
| GSK | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - General | -- |
| Last price | 50.33 | 1,354.00 |
| Change today | -0.16% | -0.79% |
| 1-year return | +10.7% | +45.3% |
| Market cap | $100.88B | $1.27T |
| 52-week range | 44.64 – 60.12 | 847.83 – 1,453.00 |
| Valuation | ||
| P/E (TTM) | 17.50 | 43.95 |
| P/E percentile, own 5-yr range | 73rd | 27th |
| P/B | 4.00 | 31.63 |
| Dividend yield | 3.56% | 0.49% |
| Profitability & growth | ||
| EPS (TTM) | 3.73 | 22.95 |
| Net profit (TTM) | $7.48B | $21.59B |
| Revenue (TTM) | $33.54B | $86.46B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +4.0% | +38.6% |
| Gross margin | 72.6% | 83.6% |
| Operating margin | 19.1% | 51.3% |
| Net margin | 13.0% | 31.9% |
| Free cash flow (TTM) | $6.26B | $11.69B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 87.9% | 79.4% |
| Insider activity (12mo) | 0 buy / 0 sell | 39 buy / 11 sell |
| Short interest (% of float) | 0.7% | 0.7% |
| Analyst consensus | 100% hold (1) | 92% buy / 4% hold / 4% sell (24) |
| Analyst price target | $56 (+11%) | $1,511 (+12%) |
| StockVane view | ||
| StockVane Quant Rating | D (50) | B (84) |
| Company | ||
| Employees | 66,841 | 50,000 |
| Founded | -- | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.